The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Using inhibitors of metalloproteinases to treat arthritis. Easier said than done?
Abstract
Collagenase and stromelysin have a premier role in the irreversible degradation of the extracellular matrix seen in rheumatic disease. It is therefore no surprise that considerable attention has been devoted to developing strategies to reduce their levels in diseased joints. Most efforts have focused on inhibiting the activity of the enzymes, either by increasing the concentration of natural inhibitors such as the TIMPs or by introducing into the joint synthetic compounds that will complex with the enzymes and inactivate them. There have also been studies directed at inhibiting enzyme synthesis. These preclinical studies have been carried out in cell-free and/or cell culture systems and in animal models. Despite promising preclinical data, there have been no stunning successes in the clinical arena. The reasons for this are several. In part, they are rooted in the technical difficulties associated with designing inhibitors of enzyme activity that are of high affinity, and then delivering them to the affected joints while still maintaining specificity and efficacy. The complicated structure of the proteoglycan and collagen that comprise articular cartilage, along with the biochemistry of inflamed synovial tissue, only compound the difficulties. In addition to these technical problems, the lack of fundamental knowledge about the biochemistry and molecular biology of the enzymes has handicapped our efforts. We are just resolving the crystal structure of the metalloproteinases (108) and beginning to understand the mechanisms controlling gene expression (67, 68, 70-72). These advances represent significant achievements in metalloproteinase enzymology and biology and should form the scientific basis for a new generation of effective therapies. For example, knowledge of the active site as derived from the crystal structure of the enzymes may facilitate the development of tightly-binding specific inhibitors which function well in vivo. Similarly, based on our current understanding of mechanisms controlling the regulation of both the TIMP genes and the MMP genes, we are beginning to elucidate how to turn these genes on or off, and hopefully, to modulate disease accordingly. Indeed, although some studies are still at a preclinical level, these possible approaches are becoming a reality (109). Arthritic diseases in general, and rheumatoid arthritis in particular, represent a complicated multifaceted set of clinical disorders. The clinical symptoms and pathologic features result from a cascade of biologic pathways that involve acute and chronic inflammation, the immune response, and metalloproteinase biochemistry.(ABSTRACT TRUNCATED AT 400 WORDS)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of a receptor for the morphogen retinoic acid
Giguere, V., Ong, E. S., Segui, P., & Evans, R. M. (1987) · Nature · doi:10.1038/330624a0 · Cited by 1,965
Multiplicity generates diversity in the retinoic acid signalling pathways
Leid, M., Kastner, P., & Chambon, P. (1992) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(92)90014-z · Cited by 821
Overall, C. M., Wrana, J. L., & Sodek, J. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)94267-5 · Cited by 636
Cited by
ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Feldmann, M., Brennan, F. M., & Maini, R. N. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.397 · Cited by 2,514
Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors
Whittaker, M., Floyd, C. D., Brown, P., & Gearing, A. J. H. (1999) · Chemical Reviews · doi:10.1021/cr9804543 · Cited by 982
Matrix Metalloproteinases and Cardiovascular Disease
Dollery, C. M., McEwan, J. R., & Henney, A. M. (1995) · Circulation Research · doi:10.1161/01.res.77.5.863 · Cited by 864
Physiology and pathophysiology of matrix metalloproteases
Klein, T., & Bischoff, R. (2011) · Amino Acids · doi:10.1007/s00726-010-0689-x · Cited by 828
Bondeson, J., Wainwright, S. D., Lauder, S., Amos, N., & Hughes, C. E. (2006) · Arthritis Research & Therapy · doi:10.1186/ar2099 · Cited by 527
Metadata
- Authors
- Vincenti, M. P., Clark, I. M., & Brinckerhoff, C. E.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 1994-12
- Volume
- 37
- Issue
- 8
- Pages
- 1115-1126
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1998549662
- Cited by
- 188
- References
- 3
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? https://app.cochat.ai/papers/10.1002/art.1780370802
- The paper
- Vincenti, M. P., Clark, I. M., & Brinckerhoff, C. E. (1994). Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? Arthritis & Rheumatism. https://doi.org/10.1002/art.1780370802
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.